Harrow (NASDAQ:HROW – Get Free Report) and Aditxt (NASDAQ:ADTX – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.
Earnings & Valuation
This table compares Harrow and Aditxt”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Harrow | $275.59 million | 5.15 | -$5.14 million | ($1.00) | -37.85 |
| Aditxt | $14,336.00 | 0.44 | -$41.71 million | ($100,788.35) | -0.00 |
Profitability
This table compares Harrow and Aditxt’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Harrow | -13.51% | -38.00% | -3.37% |
| Aditxt | -360,152.50% | -374.60% | -105.93% |
Risk & Volatility
Harrow has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500. Comparatively, Aditxt has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500.
Insider and Institutional Ownership
72.8% of Harrow shares are held by institutional investors. Comparatively, 15.5% of Aditxt shares are held by institutional investors. 12.8% of Harrow shares are held by insiders. Comparatively, 0.0% of Aditxt shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Harrow and Aditxt, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Harrow | 2 | 1 | 8 | 0 | 2.55 |
| Aditxt | 1 | 0 | 0 | 0 | 1.00 |
Harrow presently has a consensus price target of $69.43, suggesting a potential upside of 83.43%. Given Harrow’s stronger consensus rating and higher possible upside, research analysts clearly believe Harrow is more favorable than Aditxt.
Summary
Harrow beats Aditxt on 12 of the 14 factors compared between the two stocks.
About Harrow
Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.
About Aditxt
Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
Receive News & Ratings for Harrow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow and related companies with MarketBeat.com's FREE daily email newsletter.
